Use of speckle tracking echocardiography to detect late anthracycline-induced cardiotoxicity in childhood cancer: A prospective controlled cross-sectional study.


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 May 2022
Historique:
received: 04 10 2021
revised: 09 01 2022
accepted: 10 02 2022
pubmed: 16 2 2022
medline: 15 4 2022
entrez: 15 2 2022
Statut: ppublish

Résumé

This study aimed to detect late sub-clinical patterns of cardiac dysfunction using speckle tracking echocardiography (STE) in children with cancer remission more than 12 months after the end of anthracycline treatment. This prospective controlled study enrolled 196 children, 98 of which had been treated with anthracyclines (mean age 10.8 ± 3.6 years; 51% female) and 98 were age- and gender-matched healthy subjects in a 1:1 case-control design. Conventional echocardiographic variables were collected for left ventricle (LV) and right ventricle (RV). STE analyses were performed in the LV longitudinal, radial, and circumferential displacements and in the RV free wall longitudinal displacement. The association between LV global longitudinal strain (GLS) and the main clinical and biological parameters was evaluated. After a mean time interval of 5.1 ± 3.2 years since the end of chemotherapy (mean cumulative anthracycline dose of 192 ± 96 mg/m The existence of a modified LV strain despite normal LV function in children treated with anthracyclines represents an important perspective for cardiomyopathy surveillance in childhood cancer survivors. Clinical Trial Registration -ClinicalTrials.gov Identifier: NCT02893787.

Sections du résumé

BACKGROUND BACKGROUND
This study aimed to detect late sub-clinical patterns of cardiac dysfunction using speckle tracking echocardiography (STE) in children with cancer remission more than 12 months after the end of anthracycline treatment.
METHODS METHODS
This prospective controlled study enrolled 196 children, 98 of which had been treated with anthracyclines (mean age 10.8 ± 3.6 years; 51% female) and 98 were age- and gender-matched healthy subjects in a 1:1 case-control design. Conventional echocardiographic variables were collected for left ventricle (LV) and right ventricle (RV). STE analyses were performed in the LV longitudinal, radial, and circumferential displacements and in the RV free wall longitudinal displacement. The association between LV global longitudinal strain (GLS) and the main clinical and biological parameters was evaluated.
RESULTS RESULTS
After a mean time interval of 5.1 ± 3.2 years since the end of chemotherapy (mean cumulative anthracycline dose of 192 ± 96 mg/m
CONCLUSIONS CONCLUSIONS
The existence of a modified LV strain despite normal LV function in children treated with anthracyclines represents an important perspective for cardiomyopathy surveillance in childhood cancer survivors. Clinical Trial Registration -ClinicalTrials.gov Identifier: NCT02893787.

Identifiants

pubmed: 35167907
pii: S0167-5273(22)00247-9
doi: 10.1016/j.ijcard.2022.02.012
pii:
doi:

Substances chimiques

Anthracyclines 0
Antibiotics, Antineoplastic 0

Banques de données

ClinicalTrials.gov
['NCT02893787']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

75-83

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Auteurs

Pascal Amedro (P)

Paediatric and Congenital Cardiology Department, M3C National Reference Centre, Bordeaux University Hospital, Bordeaux, France; IHU Liryc, Electrophysiology and Heart Modelling Institute, Bordeaux University Foundation, Pessac, France. Electronic address: pascal.amedro@chu-bordeaux.fr.

Marie Vincenti (M)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, CHU Montpellier, Montpellier, France; PhyMedExp, University of Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.

Hamouda Abassi (H)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, CHU Montpellier, Montpellier, France.

Nicolas Lanot (N)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, CHU Montpellier, Montpellier, France.

Gregoire De La Villeon (G)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, CHU Montpellier, Montpellier, France.

Sophie Guillaumont (S)

Paediatric and Congenital Cardiology Department, M3C Regional Reference CHD Centre, CHU Montpellier, Montpellier, France.

Lucie Gamon (L)

Epidemiology and Clinical Research Department, CHU Nimes, Nimes, France.

Thibault Mura (T)

Epidemiology and Clinical Research Department, CHU Nimes, Nimes, France.

Karine Lopez-Perrin (K)

Paediatric Oncology, CHU Montpellier, Montpellier, France.

Stephany Haouy (S)

Paediatric Oncology, CHU Montpellier, Montpellier, France.

Anne Sirvent (A)

Paediatric Oncology, CHU Montpellier, Montpellier, France.

Olivier Cazorla (O)

PhyMedExp, University of Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.

Laurence Vergely (L)

Department of Pharmaceutical Oncology, CHU Montpellier, Montpellier, France.

Alain Lacampagne (A)

PhyMedExp, University of Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France.

Martina Avesani (M)

Paediatric and Congenital Cardiology Department, M3C National Reference Centre, Bordeaux University Hospital, Bordeaux, France.

Nicolas Sirvent (N)

Paediatric Oncology, CHU Montpellier, Montpellier, France.

Laure Saumet (L)

Paediatric Oncology, CHU Montpellier, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH